Microdevice study for psoriasis and eczema
Treatments studied
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This trial tests a small device to help treat psoriasis and atopic dermatitis (a common type of eczema). It may offer a new option for managing your skin condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with psoriasis or atopic dermatitis.
- If you are a woman who could become pregnant, you must be using birth control pills or an IUD for at least 30 days before starting.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two new study medicines (PF-07275315 and PF-07264660) for people with moderate to severe eczema that hasn't responded well to other treatments, including biologics. The goal is to see if these medicines can help reduce itching and clear the skin.
This trial tests a study drug (PF-08049820) for people with moderate to severe eczema who haven't found a suitable prescription treatment. It aims to see if the drug can improve skin symptoms and itching.
This trial tests whether a cosmetic cream can reduce eczema flare-ups and is comfortable/safe to use on very dry, irritated, eczema-prone skin. It’s mainly for children who have had recent flare-ups and moderate eczema severity.
This trial tests an experimental drug called BBT001 for people with moderate to severe eczema (atopic dermatitis) that hasn't been helped enough by creams. The study is in early phases, so it will check how safe the drug is and how well it might work.
This study tests whether combining two drugs, dupilumab and tofacitinib, works better for moderate to severe eczema in adults than either alone. It may help people whose eczema is not well controlled with standard treatments.
This study tests a new medication called IBI3002 for people with moderate to severe eczema (atopic dermatitis) that hasn't been well controlled by standard creams. The goal is to see if IBI3002 can reduce skin inflammation and itching.
Hear when a new Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.